Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

@article{Costelloe2012SecondaryAD,
  title={Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis},
  author={L. Costelloe and J. Jones and A. Coles},
  journal={Expert Review of Neurotherapeutics},
  year={2012},
  volume={12},
  pages={335 - 341}
}
Alemtuzumab is a humanized monoclonal antibody that causes prolonged lymphopenia. In a recent Phase III trial, alemtuzumab was shown to reduce both the annualized relapse rate and the rate of sustained accumulation of disability by over 70% when compared with IFN-β1a. However, the drug is associated with thyroid autoimmunity in approximately a third of treated patients, as well as other secondary autoimmune conditions in smaller numbers. Secondary autoimmunity typically arises during… Expand
75 Citations
Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects
  • 14
Immune status following alemtuzumab treatment in human CD52 transgenic mice
  • 47
A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis
  • 6
Drug safety evaluation of alemtuzumab for multiple sclerosis
  • 8
Alemtuzumab as Treatment for Multiple Sclerosis.
  • 3
  • PDF
Ocular Findings in Alemtuzumab (Campath-1H)-induced Thyroid Eye Disease.
  • 8
Mitigating alemtuzumab-associated autoimmunity in MS
  • 4
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 35 REFERENCES
Alemtuzumab treatment of multiple sclerosis.
  • A. Coles
  • Medicine
  • Seminars in neurology
  • 2013
  • 19
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
  • 864
  • PDF
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis
  • 146
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
  • 142
...
1
2
3
4
...